keyword
https://read.qxmd.com/read/38195322/mosunetuzumab-safety-profile-in-patients-with-relapsed-refractory-b-cell-non-hodgkin-lymphoma-clinical-management-experience-from-a-pivotal-phase-i-ii-trial
#21
JOURNAL ARTICLE
Matthew Matasar, Nancy L Bartlett, Mazyar Shadman, Lihua E Budde, Ian Flinn, Gareth P Gregory, Won Seog Kim, Georg Hess, Dima El-Sharkawi, Catherine S Diefenbach, Huang Huang, Iris To, Joana Parreira, Mei Wu, Antonia Kwan, Sarit Assouline
BACKGROUND: Mosunetuzumab is a CD20xCD3 T-cell engaging bispecific antibody approved in Europe and the United States for relapsed/refractory (R/R) follicular lymphoma (FL) after ≥ 2 prior therapies. MATERIALS AND METHODS: We present interim safety data from the mosunetuzumab GO29781 (NCT02500407) phase I/II dose-escalation study in R/R non-Hodgkin lymphoma (NHL), focusing on FL. RESULTS: Overall, 218 patients with R/R NHL, including 90 with R/R FL, received a median of eight 21-day cycles of intravenous mosunetuzumab with step-up dosing in Cycle (C) 1 (C1 Day [D] 1, 1 mg; C1D8, 2 mg; C1D15/C2D1, 60 mg; C3D1 and onwards, 30 mg)...
December 12, 2023: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38187172/tumor-lysis-syndrome-followed-by-tumor-regression-after-covid-19-in-a-patient-with-chronic-lymphocytic-leukemia
#22
JOURNAL ARTICLE
Masato Yasumi, Yudai Yamamoto, Kimimori Kamijo, Tsuyoshi Kamae, Masaya Yamato, Takahiro Karasuno
Coronavirus disease 2019 (COVID-19) can become lethal in patients with hematological malignancies; however, several cases of tumor regression after COVID-19 have been described, and the precise mechanism behind this paradoxical effect is unknown. Herein, we describe a case of Tumor lysis syndrome (TLS) followed by tumor regression after COVID-19. A 72-year-old woman with untreated chronic lymphocytic leukemia was admitted to our hospital with SARS-CoV-2 antigen-positive pneumonia. On admission, her anti-SARS-CoV-2 spike antibody was negative despite receiving two prior vaccinations...
January 2024: International cancer conference journal
https://read.qxmd.com/read/38183209/recent-advances-and-future-perspectives-of-t-cell-engagers-in-lymphoid-malignancies
#23
JOURNAL ARTICLE
Yuko Shirouchi, Dai Maruyama
Bispecific antibodies (BsAbs) are monoclonal antibodies that simultaneously bind to a specific antigen on tumors and CD3 on T cells, leading to T cell activation and subsequent tumor cell lysis. Several CD20 × CD3 BsAbs are being developed for B-cell lymphomas. Furthermore, multiple clinical trials to evaluate BsAbs for the treatment of multiple myeloma, with targets including BCMA, GPRC5D and FcRH5, are ongoing. Emerging evidence suggests promising efficacy in heavily pretreated patients with relapsed or refractory lymphoid malignancies, showing an overall response rate of 50-60%, with complete response rates of 30-40% for relapsed or refractory large B-cell lymphoma and 60-70% for relapsed or refractory multiple myeloma...
January 5, 2024: Japanese Journal of Clinical Oncology
https://read.qxmd.com/read/38174025/independent-predictors-of-mortality-and-5-year-trends-in-mortality-and-resource-utilization-in-hospitalized-patients-with-diffuse-large-b-cell-lymphoma
#24
JOURNAL ARTICLE
Zubair Hassan Bodla, Mariam Hashmi, Fatima Niaz, Umer Farooq, Farhan Khalid, Muhammad Junaid Tariq, Muhammad Jahanzeb Khalil, Victoria S Brown, Christopher L Bray
BACKGROUND: This retrospective study analyzed factors influencing all-cause inpatient mortality in 80,930 adult patients (2016-2020) with diffuse large B cell lymphoma using the National Inpatient Sample database. METHODS: Utilizing ICD-10 codes, patients were identified, and statistical analysis was conducted using STATA. Fisher's exact and Student's t tests compared proportions and variables, multivariate logistic regression examined mortality predictors, and a 5-year longitudinal analysis identified mortality and resource utilization trends...
2024: Proceedings of the Baylor University Medical Center
https://read.qxmd.com/read/38157190/phase-2-study-of-ibrutinib-plus-venetoclax-in-japanese-patients-with-relapsed-refractory-mantle-cell-lymphoma
#25
JOURNAL ARTICLE
Hideki Goto, Satoshi Ito, Masahiro Kizaki, Masaki Yamaguchi, Noriko Fukuhara, Koji Kato, Toko Saito, Yasuhito Terui, Sumiko Okubo, Tomomi Soshin, Jiewei Zeng, Hideyuki Honda, Mohamed Badawi, Jeremy A Ross, Koji Izutsu
BACKGROUND: Despite high response rates to initial therapy, most patients with mantle cell lymphoma (MCL) experience relapsed or refractory (R/R) disease. Here, we report the efficacy, safety, and pharmacokinetics of the Phase 2, single-arm M20-075 study (NCT04477486) of ibrutinib and venetoclax combination therapy in Japanese patients with R/R MCL. METHODS: Patients received 560 mg ibrutinib and 400 mg venetoclax (after a 5-week ramp-up from 20 mg) once daily for up to 104 weeks...
February 2024: International Journal of Clinical Oncology
https://read.qxmd.com/read/38138247/afatinib-induced-tumor-lysis-syndrome-in-pulmonary-adenocarcinoma-a-case-report-and-literature-review
#26
Goohyeon Hong
Tumor lysis syndrome (TLS) is a potentially fatal oncological emergency that typically develops during the treatment of rapidly proliferating malignancies. It is infrequently reported in solid tumors, such as pulmonary adenocarcinoma. A 59-year-old male patient with shortness of breath presented with a 3.3 cm × 3.0 cm mass in the right upper lobe, along with massive right-sided pleural effusion. A percutaneous needle biopsy was performed, and a diagnosis of pulmonary adenocarcinoma with an epidermal growth factor receptor ( EGFR ) mutation was made...
December 10, 2023: Medicina
https://read.qxmd.com/read/38095349/effective-treatment-with-gilteritinib-based-regimens-for-flt3-mutant-extramedullary-relapse-in-acute-promyelocytic-leukemia
#27
JOURNAL ARTICLE
Chun-Xiao Hou, Yu Chen, Shan-Hao Liu, Yi-Zhi Jiang, Dong-Ping Huang, Su-Ning Chen
OBJECTIVE: Extramedullary relapse (EMR) is rare in acute promyelocytic leukemia (APL) and, there is a lack of information on its management. Current practices for EMR in APL are always to adopt strategies from other subtypes of Acute lymphoblastic leukemia (ALL) and Acute myeloid leukemia (AML). Gilteritinib, a highly selective FLT3 inhibitor, has demonstrated a remarkable effect on EMR in FLT3-mutant AML. Therefore, it is worthwhile exploring if FLT3 mutation can be a therapeutic target and assessing the efficacy of Gilteritinib on FLT3-mutant EMR in APL...
December 2024: Hematology (Amsterdam, Netherlands)
https://read.qxmd.com/read/38091052/optimal-dosage-of-rituximab-for-children-with-burkitt-lymphoma
#28
JOURNAL ARTICLE
Shuang Huang, Ling Jin, Jing Yang, Meng Zhang, Yonghong Zhang, Yaguang Peng, Yanlong Duan, Huyong Zheng
The current chemotherapy treatments have led to an improvement in survival rates for pediatric Burkitt's lymphoma (BL). Survival in children with high-grade, mature B-cell non-Hodgkin's lymphoma (B-NHL) has been prolonged by six rituximab doses combined with chemotherapy, whereas the efficacy of four doses has not been reported. This study aimed to explore optimal therapeutic strategies-the number of doses of rituximab based on different risk groups-and also aim to investigate the clinical characteristics of Chinese pediatric BL...
December 13, 2023: Annals of Hematology
https://read.qxmd.com/read/38081189/c-x-c-motif-chemokine-receptor-4-targeted-radioligand-therapy-in-hematological-malignancies-myeloablative-effects-antilymphoma-activity-and-safety-profile
#29
JOURNAL ARTICLE
Niklas Dreher, Anna-Lena Dörrler, Sabrina Kraus, Takahiro Higuchi, Sebastian E Serfling, Samuel Samnick, Hermann Einsele, Götz Ulrich Grigoleit, Andreas K Buck, Rudolf A Werner
BACKGROUND: After C-X-C motif chemokine receptor 4 (CXCR4)-directed radioligand therapy (RLT), lymphoma patients are scheduled for conditioning therapy (CON) followed by hematopoietic stem cell transplantation (HSCT). We aimed to determine whether CXCR4-RLT can achieve bone marrow ablation and direct antilymphoma activity independent from CON/HSCT and also evaluated the safety profile of this theranostic approach in an acute setting. PATIENTS AND METHODS: After CXCR4-directed 68Ga-pentixafor PET/CT, 21 heavily pretreated patients with hematological malignancies underwent CXCR4-directed RLT using 90Y-pentixather...
December 6, 2023: Clinical Nuclear Medicine
https://read.qxmd.com/read/38066881/recognizing-defining-and-managing-car-t-hematologic-toxicities
#30
JOURNAL ARTICLE
Kai Rejeski, Marion Subklewe, Frederick L Locke
Autologous CAR-T cell therapy (CAR-T) has improved outcomes for patients with B-cell malignancies. It is associated with the well-described canonical toxicities cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), which may be abrogated by corticosteroids and the anti-IL6 receptor antagonist tocilizumab. Practitioners and researchers should be aware of additional toxicities. Here we review current understanding and management of hematologic toxicities after CAR-T, including cytopenias, coagulopathies, bleeding and clotting events, hemophagocytic-lymphohistiocytosis, and tumor lysis syndrome...
December 8, 2023: Hematology—the Education Program of the American Society of Hematology
https://read.qxmd.com/read/38034230/beyond-the-expectation-pembrolizumab-associated-tumor-lysis-syndrome-in-metastatic-gastric-adenocarcinoma
#31
Arwa Battah, Iyad Farouji, Theodore R DaCosta, Darshan Ghandi, Theodore DaCosta, Yatinder Bains
Tumor lysis syndrome (TLS) emerges as a critical oncological emergency, a consequence of the body's struggle to manage the intense cellular turnover and release of cytotoxins induced by treatments such as chemotherapy, radiation, targeted immune therapy, or hormonal therapy. While commonly associated with hematological malignancies, the heightened risk also extends to advanced-stage solid tumors and instances of liver metastasis. Although TLS is a rare occurrence in gastric adenocarcinoma, reported cases are usually linked to the initiation of chemotherapy...
October 2023: Curēus
https://read.qxmd.com/read/38009885/hyperleukocytosis-in-acute-myeloid-leukemia-considerations-for-inpatient-diagnosis-and-management
#32
JOURNAL ARTICLE
Tia T Wheatley, Haley Foster Castiglione, Kenneth Phong, Monica Yoon
Hyperleukocytosis, a white blood cell count greater than 100,000/mcl, can be associated with the following three primary oncologic emergencies: leukostasis, disseminated intravascular coagulation, and tumor lysis syndrome. Th.
November 16, 2023: Clinical Journal of Oncology Nursing
https://read.qxmd.com/read/38007380/a-case-report-of-spontaneous-tumor-lysis-syndrome-in-a-patient-with-chronic-myeloid-leukemia-treated-successfully-with-allopurinol
#33
Ariella Gartenberg, Maia Winkel, Nicole Leonard
Tumor Lysis Syndrome (TLS) is an oncologic emergency that may occur in any patient with a hematologic malignancy, even prior to initiation of chemotherapy. Spontaneous TLS massive tumor cell destruction with intracellular electrolyte release prior to the initiation of chemotherapy. Spontaneous tumor lysis syndrome is a rare presentation, mainly occurring in Acute Leukemia and non-Hodgkin Lymphoma. Chronic Myeloid Leukemia (CML) is a low-risk disease based on TLS risk stratification. To the best of our knowledge, spontaneous TLS in the chronic phase of CML successfully treated with allopurinol and aggressive hydration has yet to be reported in the literature...
November 10, 2023: American Journal of Emergency Medicine
https://read.qxmd.com/read/37990559/important-considerations-in-the-intensive-care-management-of-acute-leukemias
#34
REVIEW
Hoda Pourhassan, Waasil Kareem, Vaibhav Agrawal, Ibrahim Aldoss
In the realm of hematologic disorders, acute leukemia is approached as an emergent disease given the multitude of complications and challenges that present both as a result of inherent disease pathology and adverse events associated with antineoplastic therapies and interventions. The heavy burden of leukemic cells may lead to complications including tumor lysis syndrome, hyperleukocytosis, leukostasis, and differentiation syndrome, and the initiation of treatment can further exacerbate these effects. Capillary leak syndrome is observed as a result of antineoplastic agents used in acute leukemia, and L-asparaginase, a bacterial-derived enzyme, has a unique side effect profile including association with thrombosis...
April 2024: Journal of Intensive Care Medicine
https://read.qxmd.com/read/37971194/ibrutinib-and-venetoclax-as-primary-therapy-in-symptomatic-treatment-na%C3%A3-ve-waldenstr%C3%A3-m-macroglobulinemia
#35
JOURNAL ARTICLE
Jorge J Castillo, Andrew R Branagan, David Sermer, Catherine Flynn, Kirsten E Meid, Megan Little, Katherine Stockman, Timothy P White, Alexa G Canning, Maria Luisa Guerrera, Amanda Kofides, Shirong Liu, Xia Liu, Kris Richardson, Nicholas Tsakmaklis, Christopher J Patterson, Zachary R Hunter, Steven P Treon, Shayna Sarosiek
Concurrent BTK and BCL2 inhibition has not been investigated in Waldenström macroglobulinemia. We performed an investigator-initiated trial of ibrutinib and venetoclax in symptomatic, treatment-naive patients with MYD88-mutated WM. Patients received ibrutinib 420 mg once daily (cycle 1), followed by a ramp-up of venetoclax to 400 mg daily (cycle 2). The combination was then administered for 22 additional four-week cycles. Attainment of VGPR was the primary endpoint. Forty-five patients were enrolled. Median baseline characteristics were age 67 years, serum IgM 43 g/L, and hemoglobin 102 g/L...
October 27, 2023: Blood
https://read.qxmd.com/read/37963436/tumor-lysis-syndrome-is-associated-with-worse-outcomes-in-adult-patients-with-acute-lymphoblastic-leukemia
#36
JOURNAL ARTICLE
Fausto A Rios-Olais, Fernando Gil-Lopez, Analy Mora-Cañas, Roberta Demichelis-Gómez
INTRODUCTION: Tumor lysis syndrome (TLS) occurs frequently during induction therapy for acute lymphoblastic leukemia (ALL). Patients are categorized into intermediate or high risk based on lactate dehydrogenase (LDH) value and white blood cell (WBC) count according to an expert panel, although no effort has been made to analyze TLS in ALL and its potential consequences. METHODS: We retrospectively analyzed TLS, variables associated with its occurrence and its impact in overall survival and mortality during induction in a cohort of ALL patients in their first induction regimen...
November 14, 2023: Acta Haematologica
https://read.qxmd.com/read/37942403/relapse-of-lung-adenocarcinoma-manifested-by-spontaneous-tumor-lysis-syndrome
#37
Daebin Im, Katie Alsheimer, Joyson Poulose, Violeta Zeykan, Giampaolo Talamo
INTRODUCTION: Tumor lysis syndrome (TLS) is an oncologic emergency characterized by several metabolic derangements, such as hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia. TLS is typically observed in hematologic malignancies, especially after starting the first administration of antineoplastic therapies. TLS in a solid malignancy is very unusual, and exceedingly rare when occurring spontaneously, in the absence of chemotherapy. CASE PRESENTATION: We report a case of a 76-year-old man with lung adenocarcinoma, which started as a cancer with indolent behavior and small tumor burden but relapsed in 5 months with rapidly proliferating metastatic disease...
2023: Case Reports in Oncology
https://read.qxmd.com/read/37933203/tumor-lysis-syndrome-in-patients-with-acute-myeloid-leukemia-treated-with-venetoclax-and-hypomethylating-agents-with-or-without-dose-ramp-up
#38
JOURNAL ARTICLE
Christy J Khouderchah, Lydia L Benitez, Bernard L Marini, Martina Fraga, Kristen Pettit, Patrick W Burke, Dale L Bixby, Anthony J Perissinotti
Venetoclax with hypomethylating agents (HMAs) is an important treatment for patients with acute myeloid leukemia (AML) who cannot tolerate intensive chemotherapy. However, there is limited data on the safety of venetoclax without a dose ramp-up in patients with AML. A retrospective cohort analysis of patients with AML treated with HMA/venetoclax (HMA/Ven) with or without a dose ramp-up, or HMA alone from 6/30/2014-8/22/2022 was conducted. The primary endpoint was the incidence of laboratory and/or clinical tumor lysis syndrome (TLS) by day 10...
November 6, 2023: Leukemia & Lymphoma
https://read.qxmd.com/read/37900788/a-case-of-tumor-lysis-syndrome-during-palliative-radiotherapy-for-breast-cancer-metastases
#39
Mitsuhiro Furusawa, Kozue Matsuishi, Kei Horino, Hideki Inoue, Michio Abe, Natsuo Oya
Tumor lysis syndrome (TLS) is the rapid disintegration of a malignant tumor treated with anticancer drugs or radiation, causing electrolyte abnormalities such as elevated uric acid levels, elevated potassium and phosphorus levels, and decreased calcium levels. These abnormalities can lead to hypotension, renal dysfunction, consciousness disorders, and even death in some cases. The current patient was a 65-year-old woman who had breast cancer with local invasion, lung metastasis, and bone metastasis from the time of the initial disease onset...
2023: Case Reports in Oncology
https://read.qxmd.com/read/37871300/response-adapted-time-limited-venetoclax-umbralisib-and-ublituximab-for-relapsed-refractory-chronic-lymphocytic-leukemia
#40
JOURNAL ARTICLE
Brian T Hill, Shuo Ma, Clive S Zent, Andrea M Baran, Danielle S Wallace, Anjali S Advani, Allison M Winter, Jane N Winter, Leo I Gordon, Reem Karmali, Jane L Liesveld, Deborah A Mulford, Chris Rowland, Andrew Bui, Peter Sportelli, Hari P Miskin, Michael S Weiss, Jonathan W Friedberg, Paul M Barr
Many patients with chronic lymphocytic leukemia (CLL) will develop treatment resistance to Bruton's tyrosine kinase (BTK) inhibitors. Phosphatidylinositol-3-kinase (PI3K) inhibitors, including umbralisib, have significant clinical activity in relapsed/refractory CLL, but prolonged exposure is associated with potential toxicities. Due to the synergistic anti-tumor effects of combined PI3K and BCL-2 inhibition, we sought to explore the feasibility of response-adapted, time-limited therapy to optimize disease control while mitigating the risks of prolonged treatment...
October 23, 2023: Blood Advances
keyword
keyword
54588
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.